Condition
Coronavirus COVID-19
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Unknown2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04404244CompletedPrimary
Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic
NCT05289128Not ApplicableUnknownPrimary
EEG as Predictor of HD-tDCS Effectiveness in Long COVID-19
NCT04445610UnknownPrimary
Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?
Showing all 3 trials